[go: up one dir, main page]

WO2016019506A1 - Utilisation d'eubactérie dans la prévention et le traitement de maladies liées à un cancer colorectal - Google Patents

Utilisation d'eubactérie dans la prévention et le traitement de maladies liées à un cancer colorectal Download PDF

Info

Publication number
WO2016019506A1
WO2016019506A1 PCT/CN2014/083689 CN2014083689W WO2016019506A1 WO 2016019506 A1 WO2016019506 A1 WO 2016019506A1 CN 2014083689 W CN2014083689 W CN 2014083689W WO 2016019506 A1 WO2016019506 A1 WO 2016019506A1
Authority
WO
WIPO (PCT)
Prior art keywords
eubacterium
ventriosum
eubacterium ventriosum
staff
atcc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2014/083689
Other languages
English (en)
Inventor
Qiang FENG
Dongya ZHANG
Chuan Liu
Liang Xiao
Longqing TANG
Jun Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BGI Shenzhen Co Ltd
Original Assignee
BGI Shenzhen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BGI Shenzhen Co Ltd filed Critical BGI Shenzhen Co Ltd
Priority to CN201480080834.6A priority Critical patent/CN106687130B/zh
Priority to PCT/CN2014/083689 priority patent/WO2016019506A1/fr
Publication of WO2016019506A1 publication Critical patent/WO2016019506A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Definitions

  • the invention relates to microbiology, specifically, this invention relates to Eubacterium bacterial strains in the treatment and prevention of colorectal cancer -related diseases in the application, and also involves the composition comprising Eubacterium bacteria and its application.
  • CRC Colorectal cancer
  • IBD inflammatory bowel disease
  • CRC colorectal cancer
  • ulcerative colitis ulcerative colitis
  • the human gut microflora which contains about 100 trillion microbial organisms, plays a critical role in maintaining host health, both in the gastrointestinal tract and systemically through the absorption of metabolites (e.g. vitamins and short chain fatty acids) (Moore WE, Holdeman LV (1974) Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl Microbiol 27: 961-979, incorporated herein by reference).
  • metabolites e.g. vitamins and short chain fatty acids
  • Embodiments of the present disclosure seek to solve at least one of the problems existing in the prior art to at least some extent.
  • the present invention is based on the following findings by the inventors:
  • CRC colorectal cancer
  • MWAS Metagenome-Wide Association Study
  • the inventors identified 2 probiotic bacteria.
  • the inventors validated the probiotic bacteria in animal experiment related to colitis and CRC respectively. Results from the animal experiment demonstrated the ability of Eubacterium ventriosum and Eubacterium eligens to prevent and treat both colitis and colorectal cancer effectively.
  • Fig.l shows distribution of P-value association statistics of all microbial genes in this study.
  • the association analysis of CRC p-value distribution identified a disproportionate over-representation of strongly associated markers at lower P-values, with the majority of genes following the expected P-value distribution under the null hypothesis. This suggests that the significant markers likely represent true rather than spurious associations.
  • Fig.2 Protective effects of intragastric administration of Eubacterium ventriosum ATCC 27560 , Eubacterium ventriosum L2-12 , Eubacterium ventriosum STAFF 1042, Eubacterium eligens ATCC 27750 , Eubacterium eligens STAFF 1020 , Eubacterium eligens TSDC 10.2- 1.1 respectively on DSS-induced colitis in C57B1/ 6J considering (A) weight loss, (B) disease activity index and (C) Colon length. Data are represented as mean ⁇ standard error. Different asterisks (*) indicate significant differences (*P ⁇ 0.05, **P ⁇ 0.01, ***p ⁇ 0.001).
  • Fig.4 Effect of Eubacterium ventriosum ATCC 27560, Eubacterium ventriosum L2-12 , Eubacterium ventriosum STAFF 1042, Eubacterium eligens ATCC 27750 , Eubacterium eligens STAFF 1020, Eubacterium eligens TSDC 10.2- 1.1 respectively treatment on (A)_Disease activity indices and (B) colon histopathology. Different asterisks (*) indicate significant differences (*P ⁇ 0.05, **P ⁇ 0.01, ***p ⁇ 0.001)
  • the present application provides Eubacterium eligens or Eubacterium ventriosum for use in the prevention or treatment of colitis and/or colorectal cancer.
  • the present application provides use of Eubacterium eligens or Eubacterium ventriosum for manufacture of a medicament for prevention or treatment of colitis and/or colorectal cancer.
  • the present application provides a method for the prevention or treatment of colitis and/or colorectal cancer comprising administering an effective amount of Eubacterium eligens or Eubacterium ventriosum to a patient in need thereof.
  • the present application provides a kit comprising Eubacterium eligens or Eubacterium ventriosum and instructions for its use as a medicament.
  • the present application further provides a pharmaceutical composition comprising Eubacterium eligens or Eubacterium ventriosum and a pharmaceutically acceptable vehicle.
  • the Eubacterium eligens is a strain selected from the group consisting of Eubacterium eligens ATCC 27750, Eubacterium eligens STAFF 1020 and Eubacterium eligens TSDC 10.2- 1.1.
  • the Eubacterium ventriosum is a strain selected from the group consisting of Eubacterium ventriosum ATCC27560, Eubacterium ventriosum L2-12, and Eubacterium ventriosum STAFF 1042.
  • the Eubacterium eligens or Eubacterium ventriosum is administered in the form of living Eubacterium eligens or Eubacterium ventriosum or metabolites thereof.
  • Example 1 Identifying probiotic bacteria from 128 Chinese individuals
  • BMI body mass index
  • eGFR epidermal growth factor receptor
  • DM diabetes mellitus type 2.
  • DNA library construction was performed following the manufacturer's instruction (Illumina HiSeq 2000 platform).
  • the inventors used the same workflow as described previously to perform cluster generation, template hybridization, isothermal amplification, linearization, blocking and denaturation, and hybridization of the sequencing primers (Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55-60 (2012), incorporated herein by reference).
  • the inventors constructed one paired-end (PE) library with insert size of 350bp for each sample, followed by a high- throughput sequencing to obtain around 30 million PE reads of length 2xl00bp.
  • High quality reads were extracted by filtering low quality reads with 'N' base, adapter contamination and human DNA contamination from the raw data, and by trimming low quality terminal bases of reads at the same time. 751 million metagenomic reads (high quality reads) were generated (5.86 million reads per individual on average, Table 2).
  • the inventors created a set of 2,110,489 (2.1M) genes that were present in at least 6 subjects, and generated 128 gene abundance profiles using these 2.1 million genes.
  • the inventors used the permutational multivariate analysis of variance (PERMANOVA) test to assess the effect of different characteristics, including age, BMI, eGFR, TCHO, LDL, HDL, TG, gender, DM, CRC status, smoking status and location, on gene profiles of 2.1M genes.
  • the inventors performed the analysis using the method implemented in package "vegan” in R, and the permuted p-value was obtained by 10,000 times permutations.
  • the inventors also corrected for multiple testing using "p. adjust" in R with Benjamini-Hochberg method to get the q-value for each gene.
  • BMI body mass index
  • DM diabetes mellitus type 2
  • HDL high density lipoprotein
  • TG triglyceride
  • eGFR epidermal growth factor receptor
  • TCHO total cholesterol
  • LDL low density lipoprotein
  • the inventors examined the taxonomic differences between control and CRC -associated microbiomes to identify microbial taxa contributing to the dysbiosis. For this, the inventors used taxonomic profiles derived from three different methods, as supporting evidence from multiple methods would strengthen an association. First, the inventors mapped metagenomic reads to 4650 microbial genomes in the IMG database (version 400) and estimated the abundance of microbial species included in that database (denoted IMG species). Second, the inventors estimated the abundance of species-level molecular operational taxonomic units (mOTUs) using universal phylogenetic marker genes.
  • mOTUs species-level molecular operational taxonomic units
  • MLGs metagenomic linkage groups
  • the inventors For each IMG genome, using the NCBI taxonomy identifier provided by IMG, the inventors identified the corresponding NCBI taxonomic classification at species and genus levels using NCBI taxonomy dump files. The genomes without corresponding NCBI species names were left with its original IMG names, most of which were unclassified.
  • Clean reads (high quality reads in Example 1) were aligned to mOTU reference (total 79268 sequences) with default parameters (S. Sunagawa et al, Metagenomic species profiling using universal phylogenetic marker genes. Nature methods 10, 1196 (Dec, 2013) , incorporated herein by reference). 549 species level mOTUs were identified, including 307 annotated species and 242 mOTU linkage groups without representative genomes, which were putatively Firmicutes or Bacteroidetes.
  • the inventors constructed the colorectal cancer associated MLGs using the method described in the previous type 2 diabetes study as Qin et al. 2012, supra. All genes were aligned to the reference genomes of IMG database v400 to get genome level annotation. An MLG was assigned to a genome if > 50% constitutive genes were annotated to that genome, otherwise it was termed as unclassified. Total 87 MLGs with gene number over than 100 were selected as colorectal cancer associated MLGs. These MLGs were grouped based on the species annotation of these genomes to construct MLG species.
  • the inventors estimated the average abundance of the genes of the MLG species, after removing the 5% lowest and 5% highest abundant genes. Relative abundance of IMG species was estimated by summing the abundance of IMG genomes belonging to that species.
  • Parvimonas micra (q ⁇ 1.80xl0 "5 ), Peptostreptococcus stomatis (q ⁇ 1.80xl0 “5 ), Solobacterium moorei (q ⁇ 0.004331) and Fusobacterium nucleatum (q ⁇ 0.004565) were consistently enriched in CRC patient microbiomes across all three methods.
  • P. stomatis has been associated with oral cancer (S. Pushalkar et al, Comparison of oral microbiota in tumor and non-tumor tissues of patients with oral squamous cell carcinoma. BMC microbiology 12, 144 (2012), incorporated herein by reference), and S. moorei has been associated with bacteremia (R. M. Pedersen, H.
  • mice used for DSS-induced colitis study were prepared in SPF condition. After acclimatization, part of mice have ad libitum access to drinking water containing 3.5 - 5% DSS (dextran sodium sulfate) for five days for colitis induction.
  • DSS distal sodium sulfate
  • C57BL/6J mice were purchased from Laboratory Animal Center of Southern Medical University, China.
  • Eubacterium ventriosum ATCC 27560 and Eubacterium eligens ATCC 27750 were purchased from American Type Culture Collection (ATCC).
  • Eubacterium ventriosum L2-12 Estelle Devillard, Freda M. Mcintosh, Sylvia H. Duncan, and R. John Wallace (March 2007). Metabolism of Linoleic Acid by Human Gut Bacteria: Different Routes for Biosynthesis of Conjugated Linoleic Acid. Journal of Bacteriology 189 (6): 2566-2570.
  • mice were observed daily and recorded clinical measurements.
  • Body weights and the disease activity index (Table 6) (Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin ,LS, et al. 2009 Distinct cytokine patterns identified from multiplexprofiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis; 15(3): 341-52. incorporated herein by reference.), a composite score reflecting clinical signs of the disease (i.e. perianal soiling, rectal bleeding and diarrhea) , were assessed for mice undergoing the DSS challenge , before DSS administration and weekly after intragastric gavage Inflammation was monitored at day 15 after induction of colitis when the mice were sacrificed by cervical dislocation.
  • the colon was removed, dissected free of fat and mesentery, carefully opened, and cleaned with PBS (phosphate buffered saline). Colon length was measured. Colonic damage and inflammation were assessed blindly according to the Wallace criteria. Colon was also collected into liquid nitrogen and stored at -80 °C for ELISA (Enzyme Linked Immunosorbent Assay) examinations.
  • PBS phosphate buffered saline
  • the inventors explored the anti-inflammatory effects in vivo by testing the ability of E. eligens ATCC 27750, STAFF 1020, TSDClO.2-1.1 and E. ventriosum L2-12, STAFF 1042, ATCC 27560 respectively to recover acute colitis induced by DSS.
  • a severe acute inflammatory was observed in the colitis control group after DSS treated, and no significant protective effect was observed in mice receiving sterile culture medium.
  • ATCC 27750 27.83 ⁇ 0.52 23.58 ⁇ 1.73 -(4.25 ⁇ 0.88) -(15.29 ⁇ 3.167)
  • ATCC 27560 represents Eubacterium ventriosum ATCC 27560; L2-12 represents Eubacterium ventriosum L2-12 , STAFF 1042 represents Eubacterium ventriosum STAFF 1042, ATCC 27750 represents Eubacterium eligens ATCC 27750, STAFF 1020 represents Eubacterium eligens STAFF 1020, TSDClO.2-1.1 represents Eubacterium eligens TSDC10.2-1.1.
  • TNF-a tumor necrosis factor alpha
  • IL-10 anti-inflammatory IL-10
  • the BAB L/c mice were challenged with azoxymethane (AOM, 10 mg/kg) at the age of 10 weeks followed by a 2.0% dextran sodium sulfate (DSS) treatment in the drinking water for 7 days beginning on week 2, week 5 and week 8 to induce colitis-associated colorectal cancer (CRC).
  • AOM azoxymethane
  • DSS dextran sodium sulfate
  • BABL/c mice were purchased from Laboratory Animal Center of Southern Medical University, China.
  • RNA isolation and real-time polymerase chain reaction of cytokines tTotal RNA from colon was isolated using the Qiagen RNA isolation kit (Qiagen) according to the manufacturer's instructions, and then was used to generate the cDNA template using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) and real-time RT-PCR was performed as previously described (Bassaganya-Riera J, Reynolds K, Martino-Catt S, Cui Y, Hennighausen L, et al. (2004) Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroen- terology 127: 777-791 , incorporated herein by reference). mRNA expression of CD36, and PPARy (peroxisome pro liferator- activated receptor ⁇ ) were assessed by real-time quantitative PGR.
  • mice challenged with azoxymethane and DSS were euthanized in the tumor-bearing phase of the disease.
  • Those mice treated with E. eligens ATCC 27750 or E. eligens STAFF 1020 or E. eligens TSDC 10.2- 1.1 or E. ventriosum L2-12 or / ⁇ . ' ventriosum STAFF 1042 or E. ventriosum ATCC 27560 showed increased mRNA expression of CD36 and PPARy in the colon compared with medium-treated control group (Fig.5 , Table 9).
  • Table 5 List of 86 MLG species formed after grouping MLGs with more than 100 genes using species annotation when available.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des micro-organismes, en particulier des souches d'Eubacterium, dans le traitement et la prévention de maladies liées au cancer colorectal. L'invention porte en outre sur une composition comprenant des souches d'Eubacterium.
PCT/CN2014/083689 2014-08-05 2014-08-05 Utilisation d'eubactérie dans la prévention et le traitement de maladies liées à un cancer colorectal Ceased WO2016019506A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201480080834.6A CN106687130B (zh) 2014-08-05 2014-08-05 真杆菌属在预防和治疗结直肠癌相关疾病中的用途
PCT/CN2014/083689 WO2016019506A1 (fr) 2014-08-05 2014-08-05 Utilisation d'eubactérie dans la prévention et le traitement de maladies liées à un cancer colorectal

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2014/083689 WO2016019506A1 (fr) 2014-08-05 2014-08-05 Utilisation d'eubactérie dans la prévention et le traitement de maladies liées à un cancer colorectal

Publications (1)

Publication Number Publication Date
WO2016019506A1 true WO2016019506A1 (fr) 2016-02-11

Family

ID=55262989

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/083689 Ceased WO2016019506A1 (fr) 2014-08-05 2014-08-05 Utilisation d'eubactérie dans la prévention et le traitement de maladies liées à un cancer colorectal

Country Status (2)

Country Link
CN (1) CN106687130B (fr)
WO (1) WO2016019506A1 (fr)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017089795A1 (fr) * 2015-11-23 2017-06-01 4D Pharma Research Limited Compositions comprenant des souches bactériennes
US9839655B2 (en) 2015-11-20 2017-12-12 4D Pharma Research Limited Compositions comprising bacterial strains
US20170360856A1 (en) 2015-06-15 2017-12-21 4D Pharma Research Limited Compositions comprising bacterial strains
US9987311B2 (en) 2015-11-23 2018-06-05 4D Pharma Research Limited Compositions comprising bacterial strains
US10046015B2 (en) 2015-11-20 2018-08-14 4D Pharma Research Limited Compositions comprising bacterial strains
US10058574B2 (en) 2015-06-15 2018-08-28 4D Pharma Research Limited Compositions comprising bacterial strains
US10080772B2 (en) 2016-07-13 2018-09-25 4D Pharma Plc Compositions comprising bacterial strains
US10086022B2 (en) 2016-03-04 2018-10-02 4D Pharma Plc Compositions comprising bacterial strains
US10086021B2 (en) 2016-12-12 2018-10-02 4D Pharma Plc Compositions comprising bacterial strains
US10226489B2 (en) 2014-12-23 2019-03-12 4D Pharma Research Limited Composition of bacteroides thetaiotaomicron for immune modulation
US10456444B2 (en) 2014-12-23 2019-10-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10493112B2 (en) 2015-06-15 2019-12-03 4D Pharma Research Limited Compositions comprising bacterial strains
US10500237B2 (en) 2015-06-15 2019-12-10 4D Pharma Research Limited Compositions comprising bacterial strains
WO2020079024A1 (fr) 2018-10-15 2020-04-23 Pharmabiome Ag Consortiums de bactéries vivantes utiles pour le traitement du cancer colorectal
US10736926B2 (en) 2015-06-15 2020-08-11 4D Pharma Research Limited Compositions comprising bacterial strains
US10851137B2 (en) 2013-04-10 2020-12-01 4D Pharma Research Limited Polypeptide and immune modulation
US10987387B2 (en) 2017-05-24 2021-04-27 4D Pharma Research Limited Compositions comprising bacterial strain
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11013773B2 (en) 2011-07-14 2021-05-25 4D Pharma Research Limited Lactic acid bacterial strains
US11123378B2 (en) 2017-05-22 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11123379B2 (en) 2017-06-14 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11224620B2 (en) 2016-07-13 2022-01-18 4D Pharma Plc Compositions comprising bacterial strains
US11266698B2 (en) 2011-10-07 2022-03-08 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
US12048720B2 (en) 2017-06-14 2024-07-30 Cj Bioscience, Inc. Compositions comprising bacterial strains

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001335A1 (fr) * 1988-08-02 1990-02-22 Borody Thomas J Traitement de troubles gastro-intestinaux
CN101590081A (zh) * 2008-05-28 2009-12-02 青岛东海药业有限公司 凸腹真杆菌和两形真杆菌制剂及其应用
CN101744239A (zh) * 2008-12-01 2010-06-23 青岛东海药业有限公司 膳食纤维在制备防治便臭或便臭中毒综合征制剂中的应用
WO2012142605A1 (fr) * 2011-04-15 2012-10-18 Samaritan Health Services Agent de déploiement de recolonisation rapide
WO2013037068A1 (fr) * 2011-09-14 2013-03-21 Queen's University At Kingston Procédé de traitement de troubles de l'appareil gastro-intestinal

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001335A1 (fr) * 1988-08-02 1990-02-22 Borody Thomas J Traitement de troubles gastro-intestinaux
CN101590081A (zh) * 2008-05-28 2009-12-02 青岛东海药业有限公司 凸腹真杆菌和两形真杆菌制剂及其应用
CN101744239A (zh) * 2008-12-01 2010-06-23 青岛东海药业有限公司 膳食纤维在制备防治便臭或便臭中毒综合征制剂中的应用
WO2012142605A1 (fr) * 2011-04-15 2012-10-18 Samaritan Health Services Agent de déploiement de recolonisation rapide
WO2013037068A1 (fr) * 2011-09-14 2013-03-21 Queen's University At Kingston Procédé de traitement de troubles de l'appareil gastro-intestinal

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PETROF E.O. ET AL.: "Stool substitute transplant therapy for the eradication of Clostridium difficile infection:'RePOOPulating' the gut.", MICROBIOME, vol. 1, no. 3, 31 December 2013 (2013-12-31) *

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11013773B2 (en) 2011-07-14 2021-05-25 4D Pharma Research Limited Lactic acid bacterial strains
US11266698B2 (en) 2011-10-07 2022-03-08 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
US11414463B2 (en) 2013-04-10 2022-08-16 4D Pharma Research Limited Polypeptide and immune modulation
US10851137B2 (en) 2013-04-10 2020-12-01 4D Pharma Research Limited Polypeptide and immune modulation
US11723933B2 (en) 2014-12-23 2023-08-15 Cj Bioscience, Inc. Composition of bacteroides thetaiotaomicron for immune modulation
US10456444B2 (en) 2014-12-23 2019-10-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10226489B2 (en) 2014-12-23 2019-03-12 4D Pharma Research Limited Composition of bacteroides thetaiotaomicron for immune modulation
US10973872B2 (en) 2014-12-23 2021-04-13 4D Pharma Research Limited Pirin polypeptide and immune modulation
US11040075B2 (en) 2015-06-15 2021-06-22 4D Pharma Research Limited Compositions comprising bacterial strains
US10780134B2 (en) 2015-06-15 2020-09-22 4D Pharma Research Limited Compositions comprising bacterial strains
US10493112B2 (en) 2015-06-15 2019-12-03 4D Pharma Research Limited Compositions comprising bacterial strains
US11273185B2 (en) 2015-06-15 2022-03-15 4D Pharma Research Limited Compositions comprising bacterial strains
US11331352B2 (en) 2015-06-15 2022-05-17 4D Pharma Research Limited Compositions comprising bacterial strains
US10864236B2 (en) 2015-06-15 2020-12-15 4D Pharma Research Limited Compositions comprising bacterial strains
US11389493B2 (en) 2015-06-15 2022-07-19 4D Pharma Research Limited Compositions comprising bacterial strains
US10058574B2 (en) 2015-06-15 2018-08-28 4D Pharma Research Limited Compositions comprising bacterial strains
US11433106B2 (en) 2015-06-15 2022-09-06 4D Pharma Research Limited Compositions comprising bacterial strains
US10322151B2 (en) 2015-06-15 2019-06-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10744167B2 (en) 2015-06-15 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10736926B2 (en) 2015-06-15 2020-08-11 4D Pharma Research Limited Compositions comprising bacterial strains
US10391130B2 (en) 2015-06-15 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US20170360856A1 (en) 2015-06-15 2017-12-21 4D Pharma Research Limited Compositions comprising bacterial strains
US10500237B2 (en) 2015-06-15 2019-12-10 4D Pharma Research Limited Compositions comprising bacterial strains
US11058732B2 (en) 2015-11-20 2021-07-13 4D Pharma Research Limited Compositions comprising bacterial strains
US10610550B2 (en) 2015-11-20 2020-04-07 4D Pharma Research Limited Compositions comprising bacterial strains
US10471108B2 (en) 2015-11-20 2019-11-12 4D Pharma Research Limited Compositions comprising bacterial strains
US9839655B2 (en) 2015-11-20 2017-12-12 4D Pharma Research Limited Compositions comprising bacterial strains
US20180078585A1 (en) 2015-11-20 2018-03-22 4D Pharma Research Limited Compositions comprising bacterial strains
US9974815B2 (en) 2015-11-20 2018-05-22 4D Pharma Research Limited Compositions comprising bacterial strains
US10046015B2 (en) 2015-11-20 2018-08-14 4D Pharma Research Limited Compositions comprising bacterial strains
US10357520B2 (en) 2015-11-20 2019-07-23 4D Pharma Research Limited Compositions comprising bacterial strains
US10391128B2 (en) 2015-11-23 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
EA034911B1 (ru) * 2015-11-23 2020-04-06 4Д Фарма Рисёрч Лимитед Композиции для лечения или профилактики воспалительного или аутоиммунного заболевания или состояния, содержащие штамм eubacterium contortum
EP3659613A1 (fr) * 2015-11-23 2020-06-03 4D Pharma Research Limited Compositions comprenant des souches bactériennes
EP3209309B1 (fr) 2015-11-23 2018-03-14 4D Pharma Research Limited Compositions comprenant des souches bactériennes
GB2560139B (en) * 2015-11-23 2021-12-22 4D Pharma Res Ltd Compositions comprising strains of Eubacterium contortum
US10744166B2 (en) 2015-11-23 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
EP3360558A1 (fr) * 2015-11-23 2018-08-15 4D Pharma Research Limited Compositions comprenant des souches bactériennes
WO2017089795A1 (fr) * 2015-11-23 2017-06-01 4D Pharma Research Limited Compositions comprenant des souches bactériennes
GB2560139A (en) * 2015-11-23 2018-08-29 4D Pharma Res Ltd Compositions comprising bacterial strains
EP4029511A1 (fr) * 2015-11-23 2022-07-20 4D Pharma Research Limited Compositions comprenant des souches bactériennes
US9987311B2 (en) 2015-11-23 2018-06-05 4D Pharma Research Limited Compositions comprising bacterial strains
US10583158B2 (en) 2016-03-04 2020-03-10 4D Pharma Plc Compositions comprising bacterial strains
US10086022B2 (en) 2016-03-04 2018-10-02 4D Pharma Plc Compositions comprising bacterial strains
US10086023B2 (en) 2016-03-04 2018-10-02 4D Pharma Plc Compositions comprising bacterial strains
US10967010B2 (en) 2016-07-13 2021-04-06 4D Pharma Plc Compositions comprising bacterial strains
US10960031B2 (en) 2016-07-13 2021-03-30 4D Pharma Plc Compositions comprising bacterial strains
US10080772B2 (en) 2016-07-13 2018-09-25 4D Pharma Plc Compositions comprising bacterial strains
US10086020B2 (en) 2016-07-13 2018-10-02 4D Pharma Plc Compositions comprising bacterial strains
US10610548B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Compositions comprising bacterial strains
US11224620B2 (en) 2016-07-13 2022-01-18 4D Pharma Plc Compositions comprising bacterial strains
US10610549B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Composition comprising bacterial strains
US10898526B2 (en) 2016-12-12 2021-01-26 4D Pharma Plc Compositions comprising bacterial strains
US10086021B2 (en) 2016-12-12 2018-10-02 4D Pharma Plc Compositions comprising bacterial strains
US10543238B2 (en) 2016-12-12 2020-01-28 4D Pharma Plc Compositions comprising bacterial strains
US10485830B2 (en) 2016-12-12 2019-11-26 4D Pharma Plc Compositions comprising bacterial strains
US11123378B2 (en) 2017-05-22 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11376284B2 (en) 2017-05-22 2022-07-05 4D Pharma Research Limited Compositions comprising bacterial strains
US11382936B2 (en) 2017-05-22 2022-07-12 4D Pharma Research Limited Compositions comprising bacterial strains
US10987387B2 (en) 2017-05-24 2021-04-27 4D Pharma Research Limited Compositions comprising bacterial strain
US11660319B2 (en) 2017-06-14 2023-05-30 4D Pharma Research Limited Compositions comprising bacterial strains
US11123379B2 (en) 2017-06-14 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11779613B2 (en) 2017-06-14 2023-10-10 Cj Bioscience, Inc. Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US12048720B2 (en) 2017-06-14 2024-07-30 Cj Bioscience, Inc. Compositions comprising bacterial strains
WO2020079024A1 (fr) 2018-10-15 2020-04-23 Pharmabiome Ag Consortiums de bactéries vivantes utiles pour le traitement du cancer colorectal

Also Published As

Publication number Publication date
CN106687130B (zh) 2020-01-21
CN106687130A (zh) 2017-05-17

Similar Documents

Publication Publication Date Title
CN106687130B (zh) 真杆菌属在预防和治疗结直肠癌相关疾病中的用途
WO2016019505A1 (fr) Utilisation d'eubacterium dans la prévention et le traitement de maladies liées à un cancer colorectal
Sun et al. The role of Fusobacterium nucleatum in colorectal cancer: from carcinogenesis to clinical management
Geurtsen et al. Genomics and pathotypes of the many faces of Escherichia coli
Sun et al. Role of the oral microbiota in cancer evolution and progression
Lin et al. Pathogenic effects of Desulfovibrio in the gut on fatty liver in diet-induced obese mice and children with obesity
Duranti et al. Elucidating the gut microbiome of ulcerative colitis: bifidobacteria as novel microbial biomarkers
Johnston et al. Loss of microRNA-21 influences the gut microbiota, causing reduced susceptibility in a murine model of colitis
Stringer et al. Irinotecan‐induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile
Urbaniak et al. The microbiota of breast tissue and its association with breast cancer
Taverniti et al. Probiotics modulate mouse gut microbiota and influence intestinal immune and serotonergic gene expression in a site-specific fashion
He et al. Probiotics mitigate Helicobacter pylori‐induced gastric inflammation and premalignant lesions in INS‐GAS mice with the modulation of gastrointestinal microbiota
Sun et al. Evolutionary biologic changes of gut microbiota in an ‘adenoma-carcinoma sequence’mouse colorectal cancer model induced by 1, 2-Dimethylhydrazine
Muszyński et al. Esophageal cancer and bacterial part of gut microbiota–a multidisciplinary point of view
Kim et al. Persistent changes in liver methylation and microbiome composition following reversal of diet-induced non-alcoholic-fatty liver disease
Zhang et al. Development of an XBP1 agonist, HLJ2, as a potential therapeutic agent for ulcerative colitis
CN114886120A (zh) 格氏乳杆菌lg-7的应用
Gong et al. Mesenteric adipose tissue‐derived Klebsiella variicola disrupts intestinal barrier and promotes colitis by type VI secretion system
Zhang et al. Probiotics treatment ameliorated mycophenolic acid-induced colitis by enhancing intestinal barrier function and improving intestinal microbiota dysbiosis in mice
CN111518932A (zh) 一种以粪便为样本检测和判定幽门螺旋杆菌耐药性的诊断方法及试剂盒
Zhang et al. Qi-Long-Tian capsule alleviates pulmonary fibrosis development by modulating inflammatory response and gut microbiota
CN117815273A (zh) 一株显著提高宿主ERβ表达量的长双歧杆菌长亚种及其应用
Sun et al. Microbiome in colonic carcinogenesis
WO2021004373A1 (fr) Utilisation d'un gène mate1 dans le traitement du cancer colorectal
HK1234335B (zh) 真杆菌属在预防和治疗结直肠癌相关疾病中的用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14899262

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14899262

Country of ref document: EP

Kind code of ref document: A1